mraoraor / iStockphoto.com
7 February 2018Americas
Teva goes to war with Eli Lilly over migraine breakthrough
Teva sued Eli Lilly yesterday in a bid to protect its IP rights covering “breakthrough treatments for migraine headaches”.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Big Pharma
17 November 2017 The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).
Americas
1 October 2018 Teva has once again taken Eli Lilly to court over a migraine drug, just hours after Eli Lilly’s gained Food and Drug Administration approval to market Emgality.
Big Pharma
4 January 2019 Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.
Editor's picks
Editor's picks
Big Pharma
17 November 2017 The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).
Americas
1 October 2018 Teva has once again taken Eli Lilly to court over a migraine drug, just hours after Eli Lilly’s gained Food and Drug Administration approval to market Emgality.
Big Pharma
4 January 2019 Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.
Big Pharma
17 November 2017 The English High Court has refused to grant Eli Lilly an injunction which would have stopped Teva, Actavis and Mylan marketing a generic version of its drug Cialis (tadalafil).
Americas
1 October 2018 Teva has once again taken Eli Lilly to court over a migraine drug, just hours after Eli Lilly’s gained Food and Drug Administration approval to market Emgality.
Big Pharma
4 January 2019 Teva Pharmaceuticals has announced that it has resolved a dispute with Amgen over Teva’s generic cinacalcet HCI product.